Accurate and timely measurements of hemoglobin A 1c (Hb A 1c ) 2 are an increasingly important challenge for clinical laboratories. As Hb A 1c measurements are being used to answer new clinical questions, each new use of Hb A 1c imposes requirements for the analytical performance of the methods used to measure it. Until recently, Hb A 1c was used only as a key test for monitoring glycemic control in people with diabetes. More recently, it has been proposed as the preferred test for the diagnosis of diabetes (1, 2 ) , and it is being used in many areas to calculate an estimated average glucose (eAG) concentration (3, 4 ) .
The analytical requirements differ in these 3 uses of the test. In monitoring glycemic control, as with any test used for monitoring therapy, the reproducibility of Hb A 1c assays is critical. Freedom from bias, however, has also become critical, because fixed cutpoints are being used as targets for glycemic control. When Hb A 1c is used for measuring eAG concentrations, errors in the measurement may produce unexpectedly large changes in eAG. In the diagnosis of diabetes, fixed cutpoints are used, again requiring particular attention to the effect of bias on diagnostic accuracy. In addition to analytical requirements, there is pressure for rapid return of results in view of evidence that improved glycemic control can be achieved when Hb A 1c results are made available at the point of care (POC) (5, 6 ) . It is against this background that an important new report addresses the analytical performance of POC assays for Hb A 1c .
In this issue of Clinical Chemistry, Lenters-Westra and Slingerland (7 ) report on the imprecision, bias, and total error of 8 POC Hb A 1c analyzers. The study used well-defined protocols from the CLSI and 3 appropriate secondary reference measurement procedures. Two of the 8 manufacturers withdrew from the study after initial unpromising results with their POC methods. Only 2 methods met an acceptance criterion of a total CV Ͻ3% in the clinically relevant concentration range, and only these 2 methods met the Ͻ0.85% error criterion of the National Glycohemoglobin Standardization Program (NGSP) with 2 different lots of reagent. These results have important clinical implications for monitoring therapy, calculating the eAG, and diagnosing diabetes or estimating the risk of developing diabetes.
Hb A 1c in Monitoring of Glycemic Control and Calculation of eAG
When monitoring serial results for an assay, laboratories commonly follow the guideline that analytical imprecision should be less than one half the biological within-person imprecision (8 ) . The CV for the mean within-person variation of Hb A 1c derived from 6 studies is approximately 3.5% (http://www.westgard.com/ guest17.htm; accessed October 27, 2009). Thus, under this guideline the desirable analytical variation for Hb A 1c would be a CV of Ͻ2%. Although this Ͻ2% criterion can be met by several laboratory-based analyzers, only 2 of the POC analyzers evaluated by LentersWestra and Slingerland met this criterion. Statisticalmodeling studies have also questioned the ability of POC devices to detect clinically important changes in Hb A 1c (9 ) .
For the use of Hb A 1c in calculating eAG (3 ), it is important to consider total error. The data of LentersWestra and Slingerland showed total-error estimates that ranged from Ϫ1.56% to ϩ1.20% Hb A 1c units. At an underlying Hb A 1c of 7%, these total errors translate into relative errors of Ϫ22% to ϩ17% in Hb A 1c . Such errors give even larger errors in eAG, Ϫ29% to ϩ22%. Such errors exceed the International Organization for Standardization total-error limit of 20% that is currently used for glucose meters, a limit that itself has been criticized as too lax to meet medical needs (10 ) .
Hb A 1c in the Diagnosis of Diabetes
Hb A 1c is recommended as the preferred test for the diagnosis of diabetes (1 ) . This recommendation reflects, among other things, the important advances in the harmonization and standardization of Hb A 1c assays that have been achieved by manufacturers working with national and international groups [e.g., (11, 12 ) ].
The International Expert Committee report on the role of Hb A 1c in the diagnosis of diabetes (1 ) recommended that testing be performed in a central laboratory, noting that POC instruments have not yet been shown to be sufficiently accurate or precise for diagnosing diabetes (1 ) . The data of Lenters-Westra and Slingerland (7 ) reinforce this viewpoint and suggest that most POC analyzers are not up to the task.
The danger of the use of POC Hb A 1c analyzers for diagnosis can be appreciated by examining Hb A 1c results for the general population of people with no history of diabetes, that is, the population of individuals who would be tested for the diagnosis of diabetes. At the recommended cutpoint of 6.5% for the diagnosis of diabetes, 2.4 ϫ 10 6 US adults are projected to have diabetes (13 ) (Fig. 1) . Errors of measurement of Hb A 1c will dramatically alter that prevalence. If, for example, Hb A 1c is measured with a bias of ϩ0.5% Hb A 1c units (so that the true Hb A 1c concentration is 0.5% units lower than the measured value), the prevalence of diabetes would nearly triple, from 2.4 ϫ 10 6 to 7.1ϫ 10 6 people ( Fig. 1) . Among the POC devices tested by Lenters-Westra and Slingerland, biases ranged from approximately Ϫ0.9% to 0.4% Hb A 1c units. If such biases were present in diagnostic testing, either tens of millions of people would be wrongly diagnosed with diabetes, with the accompanying costs, or millions would not receive diabetes treatment of proven value.
Similarly, a study of POC analyzers reported that "18% of patients with HbA1c more than 7% by laboratory analysis were not identified as such by the POC test" (14 ) . Thus, the accumulating evidence further supports the recommendation (1 ) that no POC device for measuring Hb A 1c be used for the diagnosis of diabetes in the absence of evidence that it can meet analytical requirements appropriate for that use.
Are Current Quality Specifications for Hb A 1c Measurement Adequate to Meet Clinical Needs?
The current quality specifications are not congruent with a desirable imprecision criterion based on biological variation. Currently, the NGSP requires that total error be demonstrated to be Ͻ0.85% Hb A 1c units for certification of Hb A 1c assays by manufacturers. At an Hb A 1c of 7% and with an Hb A 1c assay with zero bias, this criterion translates into a total error of Ͻ12.1% and thus to an assay imprecision CV of less than approximately 6%. This CV is more than 3 times the desirable criterion of a CV Ͻ2% described above.
There is increasing recognition of a need to improve the precision of Hb A 1c assays, in view of the low biological variability of Hb A 1c . The NGSP plans to reduce the acceptability specification for level 1 laboratories to 0.70% and for manufacturers of all Hb A 1c methods to Ͻ0.75% in 2010 (http://www.ngsp.org/ ngsp/prog/News/manuf09.html; accessed October 28, 2009). The College of American Pathologists (CAP) also has recognized the need to tighten total error criteria for Hb A 1c and is in the process of revising the criteria used in grading proficiency tests (http://www. ngsp.org/ngsp/prog/News/manuf09.html; accessed October 28, 2009). In 2007, the limit specified by the CAP for acceptability on Hb A 1c proficiency testing was Ϯ15% of the target value. This limit was lowered to Ϯ12% in 2008 and to Ϯ10% in 2009, and it will be lowered to Ϯ8% in 2010 and to Ϯ6% in 2011.
The CAP's 2011 criterion of Ϯ6% translates to an expected assay CV for imprecision of no more than 3%, and to even lower CV values in the presence of bias. These limits approach the desirable CV of Ͻ2% based on within-person biological variation. The data of Lenters-Westra and Slingerland (7 ) indicate that the manufacturers of most POC analyzers have their work cut out for them. The advances made in the analytical performance of laboratory-based Hb A 1c analyzers suggest that meeting this criterion may be possible.
For the diagnosis of diabetes, it is clear from Fig. 1 that even small biases, especially positive biases, translate into misdiagnoses in large numbers of people. More consideration of this issue is needed, but it is clear that the biases of most POC Hb A 1c analyzers reported by Lenters-Westra and Slingerland preclude their use for the diagnosis of diabetes.
The work of Lenters-Westra and Slingerland (7 ) should bring attention to the issues surrounding all Hb A 1c analyzers, both POC-based and laboratory-based. We suggest that the marketing and sale of Hb A 1c devices be contingent on the demonstration of analytical characteristics consistent with the intended uses of Hb A 1c test results. The performance of some devices may be found adequate for one use (such as monitoring of therapy in diabetes) and not for another (e.g., diagnosis of diabetes). In places where payments are made to clinicians for testing, it would seem foolhardy to pay for Hb A 1c testing of patients for the diagnosis of diabetes by a method that is not adequate for the purpose. Thus, the data of Lenters-Westra and Slingerland may take on significance for agencies such as the Food and Drug Administration and the Centers for Medicare and Medicaid Services in the US, and similar agencies elsewhere.
Lenters-Westra and Slingerland are to be thanked for providing a study that brings attention and facts to these important issues.
